| Record | OBS-0570 |
|---|---|
| Category | Health/Vaccines |
| Status | PARTIALLY SUBSTANTIATED |
| Summary | Disease mongering is the practice of pharmaceutical companies expanding markets by medicalizing normal experiences or exaggerating the severity of conditions. Proponents claim that companies invent or exaggerate diseases to sell more drugs, often through marketing disguised as awareness campaigns. This practice is documented in medical literature, though the extent and intent are debated. |
| Origin | The term 'disease mongering' emerged in the early 1990s in medical literature, with notable examples like 'low T' and restless leg syndrome campaigns. |
| Claimed |
|
| Evidence / consensus | Medical literature and experts confirm that disease mongering occurs, with documented cases of over-medicalization and marketing tactics. However, it is not a conspiracy but a recognized industry practice, and not all pharmaceutical marketing is disease mongering. |
Sources are external and provided for verification. Listing does not imply the Observer endorses their claims.